Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Ansell, Stephen M  [Clear All Filters]
2024
Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JVillasboas, Rosenthal A, et al. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 2024.
2023
Porrata LF, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Paludo J, Durani U, Markovic SN. Day 100 Natural Killer Cell/CD14+HLA-DR ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. Clin Transplant. 2023:e15211.
Stuver R, Horwitz SM, Advani RH, Vose JM, Lee HJu, Mehta-Shah N, Zain JM, Haverkos B, Lechowicz MJo, Moskowitz AJ, et al. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma. Br J Haematol. 2023.
Desai SH, Spinner MA, Evens AM, Sýkorová A, Bachanova V, Goyal G, Kahl BS, Dorritie KA, Azzi J, Kenkre VP, et al. Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. Blood Adv. 2023.
V JFHowick, Rezkalla JA, Tilbury T, Mankad SV, Bennett CE, Herrmann J, Barsness G, Ansell SM, Read MD. Venoarterial Extracorporeal Membrane Oxygenation After Autologous Stem Cell Transplantation With Pancytopenia: JACC Patient Care Pathways. J Am Coll Cardiol. 2023.
2022
Ansell SM. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(11):1478-1488.
Kosydar S, Ansell SM. Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse. Leuk Lymphoma. 2022:1-13.
N Bennani N, Kim HJin, Pederson LD, Atherton PJ, Micallef IN, Thanarajasingam G, Nowakowski GS, Witzig T, Feldman AL, Ansell SM. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022;10(6).
Wudhikarn K, Johnson BM, Inwards D, Porrata L, Micallef I, Ansell SM, Hogan W, Paludo J, Villasboas J, Johnston P. Outcomes of older adults with non-Hodgkin lymphoma undergoing autologous stem cell transplantation: a Mayo Clinic Cohort Analysis. Transplant Cell Ther. 2022.
Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JVillasboas, Rosenthal A, et al. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2022.
2021
Khurana A, Hathcock M, Habermann TM, Saleh AAl, Gandhi S, Truong T, N Bennani N, Paludo J, Villasboas JC, Ansell SM, et al. Lines of Therapy before Autologous Stem Cell Transplant and CAR-T Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma. Am J Hematol. 2021.
2020
Ansell SM. Hodgkin Lymphoma: 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020.
Moreira CL, M Sidiqi H, Buadi FK, Litzow MR, Gertz MA, Dispenzieri A, Russell SJ, Ansell SM, Stegall MD, Prieto M, et al. Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. Transplantation. 2020.
2019
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Markovic SN. Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis. Leuk Res. 2019;81:1-9.
2016
Porrata LF, Burgstaler EA, Winters JL, Jacob EK, Gastineau DA, Suman VJ, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, et al. Immunologic Autograft Engineering and Survival in Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2016.
2015
Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, et al. Dacetuzumab plus R-ICE as salvage therapy for patients with DLBCL relapsing after R-CHOP: a randomized, double-blind, placebo-controlled Phase 2b trial. Leuk Lymphoma. 2015:1-24.
2013
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Bone Marrow Res. 2013;2013:658371.